Vietnam's transplant diagnostics market is emerging as one of Southeast Asia's promising healthcare segments, driven by increasing transplant activity, greater adoption of molecular diagnostics, and continued investment in advanced laboratory capabilities.

While the market remains relatively modest in size, industry estimates place its value at approximately US$10–12 million in 2025, with projections suggesting it could grow to US$18–20 million by 2030, representing an annual growth rate of around 8–10%.

Several factors are contributing to this momentum:

• Rising prevalence of chronic kidney and liver disease, increasing the demand for organ transplantation.
• Expansion of kidney, liver, heart, and stem cell transplant programs across Vietnam's leading hospitals.
• Growing adoption of advanced diagnostic technologies, including HLA typing, PCR-based assays, next-generation sequencing (NGS), antibody screening, and crossmatching.
• Continued government investment in modern laboratory infrastructure and precision medicine.

Reagents and consumables currently account for the largest share of the market, reflecting the recurring demand for diagnostic testing throughout the transplant pathway. Molecular diagnostic techniques are expected to remain the fastest-growing technology segment as transplant centres continue to modernise.

Global diagnostics companies such as Thermo Fisher Scientific, Bio-Rad Laboratories, QIAGEN, Abbott, CareDx, and Immucor are well positioned to support Vietnam's expanding transplant ecosystem through advanced testing platforms and laboratory solutions.

As Vietnam continues to strengthen its healthcare infrastructure and increase access to organ transplantation, the country's transplant diagnostics market is expected to play an increasingly important role in improving patient outcomes and supporting precision transplant medicine.